Navigation Links
Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
Date:10/24/2007

ere observed. Two events of clinically asymptomatic Grade 3 QTc prolongation occurred in two of four patients enrolled at the 350 mg dose when read by machine. On manual re-read these events were determined to be Grade 2. The dose of 300 mg was declared to be the MTD when administered daily.

The adverse event profile in phase 2 was consistent with phase 1: the most common adverse events were Grade 1 and 2 diarrhea, rash, fatigue, and nausea. Clinically asymptomatic QTc prolongation was also observed.

About the Phase 2 Trial of XL647 as First-Line Therapy

This open-label phase 2 trial is ongoing in previously untreated patients with stage IIIB or IV NSCLC who have adenocarcinoma histology and meet one of the following three criteria: Asian descent, female gender, or no or minimal smoking history. XL647 is administered orally at a dose of 350 mg on Days 1-5 of repeated 14-day cycles. The trial is designed to enrich for patients with activating mutations in the EGF receptor (EGFR) which have been associated with improved sensitivity to other EGFR inhibitors. Based on the selection criteria, Exelixis anticipates that approximately 30 percent of subjects in the trial will have activating EGFR mutations. This design should allow the accumulation of data for patients with and without EGFR mutations, helping to identify those patients most likely to benefit from treatment with XL647.

About XL647

XL647 is a potent inhibitor of receptor tyrosine kinases (RTKs) that are implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). XL647 inhibits EGFR, HER2 and VEGFR2. The compound has been optimized for high potency and oral bioavailability, demonstrates excellent activity in target-specific cellular functional assays, and has shown sustained inhibition of target RTKs in vivo in preclinical models following a single oral dose. Two phase 2 trials in patients with NSCLC are ongoing.

About Exelixis

Exe
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and PITTSBURGH , Aug. 28, ... today announced that its shareholders have approved Mylan,s ... PRGO ; TASE) and the related issuance of ... extraordinary general meeting of shareholders held today. The ... at the extraordinary general meeting. In addition, the ...
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care ... improving outcomes and the cost of healthcare delivery ... AEX: PHIA) today announced its presence at  ESC Congress 2015 , ... Heart Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect ...
(Date:8/27/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... healthcare conferences.  , James E. ... Rodman & Renshaw Investment Conference on Thursday, September 10 ... held at the St. Regis Hotel in ... of the presentation will be available by accessing ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4DURECT to Participate in Upcoming Healthcare Conferences 2
(Date:8/28/2015)... ... 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance ... A Mission” benefit concert in Mendon, IL. Held in the Show Barn at the ... music education programs in the underfunded local school districts of Mendon at neighboring Quincy, ...
(Date:8/28/2015)... ... 28, 2015 , ... Altima Technologies, Inc., the maker of ... center assets and audio-video devices, recently released Visio Stencils for the following product ... Gen9, EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data Systems Virtual ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF International ... adolescent residential, counseling, day treatment and intensive family based services. , By pursuing ... quality and its pursuit of excellence. As a nonprofit charity for more than ...
(Date:8/28/2015)... ... , ... Northridge dentists Dr. Elyson and Dr. Assili are now ... currently receive a one hour treatment of this teeth whitening option. Zoom whitening ... of unique features that can turn teeth up to nine shades whiter. Effective on ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... which is dedicated to distributing health information technology innovation to transform quality and ... Results of the survey will be de-identified and aggregated before being publicly shared ...
Breaking Medicine News(10 mins):Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2
... , , ... an effort to help brokers, employers and employees reap the ... carbon footprint, The Guardian Life Insurance Company of America ... and small businesses, is launching a campaign focusing on its ...
... the University of Helsinki, Finland, and the Paul Scherrer ... structure of the ligand binding domain of a vascular ... of its ligands (VEGF-C). Cancer cells require access ... metastasis. By releasing VEGFs, cancer cells stimulate the surrounding ...
... the amount teenage minority boys smoke but does not ... a new study from the Indiana University School of ... March 2010 issue of the American Journal of ... under "First Look" at http://ajph.aphapublications.org/first_look.shtml . While ...
... study finds, , TUESDAY, Jan. 19 (HealthDay News) -- The more ... it, a new study finds. , The finding came from a ... diet plans. The simpler plan provided shopping lists for dieters and ... assigned point values to every food and instructed participants to eat ...
... EET Reno is ... of a Rapid Prototyping line increases the flexibility and services available to its new and ... (PRWEB) January ... high speed Rapid Prototyping line for its plant in Reno, Nevada. This strategic addition ...
... ... rapidly-growing network of retailers carrying its over-the-counter (OTC) pain reliever, Cobroxin, by expanding ... national sponsorships, and additional print advertising. , ... Delray Beach, FL (Vocus) January 19, 2010 ...
Cached Medicine News:Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 2Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 3Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 4Health News:Minority teen boys smoke more when they perceive discrimination; girls do not 2Health News:Complex Weight-Loss Plans Erode Dieters' Resolve 2Health News:EE Technologies Adds High Speed Rapid Prototyping Line in Reno 2Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 2Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 3Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 4Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 5
Guthrie fixation hook, sharp double prongs....
... lenses will feel good when you first put ... 12 hours later? Many lenses start to feel ... look blurry. But with Proclear lenses, youll enjoy ... This exceptional level of comfort is made possible ...
Designed to allow very easy handling....
The convenience of disposable type lenses available in a wide variety of options. Recommended replacement schedule: one week for extended wear, two weeks for daily wear....
Medicine Products: